FDA Investigator Joel D Martinez

Joel D Martinez has inspections in 26 countries as of 26 Oct 2023. Joel D Martinez has collaborated with a combinined 3643 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
338
Last Inspection Date:
26 Oct 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
100007445
Country:
United States of America, South Africa, France, India, Brazil, Hungary, Russian Federation, Austria, Canada, Panama, Germany, United Kingdom of Great Britain and Northern Ireland, Denmark, Portugal, Italy, Argentina, Poland, Czechia, Costa Rica, Australia, Peru, Ecuador, Chile, Dominican Republic, Lithuania
Co-Investigator(s):
Akbar J Zaidi, Albert F Peacock, PhD, Albert Peacock, PhD, Allen F Hall, Amanda J White, Andrea A Branche, Andrew J Barrowcliff, Anh M Lac, Anitha P Govada, Anthony E Keller, RPh, Anthony J Ladner, Anya D Lockett Evans, Arsen Karapetyan, Audrey J Yarbrough, Barbara M Frazier, Bhanu M Kannan, Bijoy Panicker, Blondell W Johnson, Bobbi J Miller, Brenda G Stewart Munoz, Brenda Stewart Munoz, Brian J Ryan, Byungja E Marciante, Camerson E Moore, Camille D Brown, Charles D Brown, Chmura, Christina D Mello, Christopher D Rush, Christopher J Smith, Connie Hannon Rabel, Connie L Hannon Rabel, Conrad J Ledet, Constance M Dobbins, Corrine M Carter, Courtney N Long, Cynthia A Harris, MD, RN, Cynthia F Kleppinger, MD, Daniel J Lahar, Daniel L Aisen, Daniel S Fam, Daniell Gill, Jr, Danielle Lyke, Danny D Horner, Darla J Christopher, David M Beltran, David R Heiar, Denise L Burosh, Deniza Karacic, Diana L Ayala, Diane Cvan Leeuwen, Diane L Raccasi, Dr. Barbara D Paul, PhD, Dr. Jason R Caballero, Dr. Ralph M Bernstein, PhD, Dr. Sriram Subramaniam, PhD, Edward D Edmiston, Edward D Mcdonald, Eileen A Liu, Elisa M Fleming, Eliza M Fleming, Elkins, Ellen J Tave, Elvia J Cervantes, Emilio O Escobar, Eric M Mueller, PharmD, F D Herd, Frederic W French, III, H Ljamilla Selby, Habacuc V Barrera, Hala L Selby, Hugh M Mcclure, II, Hung V Le, Iris C Macinnes, James C Henry, James H Robinson, Janet B Abt, Janete F Guardia, Janice M Hickok, Jeanne D Shaffer, Jeffrey R Wooley, Jennifer Owens Dowdy, Jeremy W Rotton, Joanne M Schlossin, Jocelyn C Turner, Jodi M Gatica, Johann M Fitch, Jonaida Estevez Martinez, Jose Alopez Rubet, Jose Martinez, Jr, Karen C Daugherty, Karen M Cooper, Karen M Kondas, Kathleen Chmura Shaffer, Kathryn A Krentz, Kelly D Sheppard, Khairy W Malek, MD, Kirstida Patel, Kirtida Patel, Kristen Nickens, PhD, Lakecha N Lewis, Lakshmi Narasimhan, PhD, Lance D Johnson, Lance M De Souza, MBA, Latorie S Jones, Laura Fontan, MS, Laurie Nelson, Leighton K Ngai, Lillie M Young, Linda F Murphy, Linda M Hoover, Linda Thai, Lindsey Brown, PhD, Lisa A Doyle, Lisa M Puttonen, Lloyd D Payne, Lorie S Hannappel, Lourdes Valentin, Lucas B Leake, Maira P Brading, Maotang Zhou, PhD, Marc R Dickens, Margaret M Annes, Maria Gutierrez Lugo, PhD, Marilyn S Babu, Mark W Babbitt, Marla A Cassidy, Martin K Yan, PhD, Martinez, Merry Christie, PhD, Michael Shanks, MS, Michele L Obert, Michelle A Krayer, Mike M Rashti, Mohsen Rajabi Abhari, FDA, Monique S Frazier, Muralidhara B Gavini, PhD, Myra K Casey, Nancy A Bellamy, Neali H Lucas, Ni A Khin, MD, Nicole M Bell, Patrice S Hall, Patrick D Stone, MS, Patrick J Mcneilly, Patty P Kaewussdangkul, Paula J Perry, Philip M Steele, PhD, Phillip D Waldron, Ralph H Vocque, Rebecca C O Bryan, Rebecca Rodriguez, Regina T Brown, Rene R Ramirez, Reyes Candau Chacon, PhD, Rhonda L Dash, Rian L Pope, Richard T Riggie, Richard W Berning, Robert D Tollefsen, Robert M Tillman, Robert T Lorenz, Roy Baby, Ruben C Ayala, PharmD, S Lori Brown, PhD MPH, Saijal P Naik, Sandra A Hughes, Sandy J Ziegler, Sarah Kennett, PhD, Scott B Laufenberg, Scott T Ballard, Selina M Mata, Shawn E Larson, Sherri N Rohlf, MD, Sherrie L Krolczyk, Shirley J Berryman, Srinivas R Chennamaneni, PhD, State Agency, Stephen D Brown, Stephen L Beekman, Stephen R Souza, Susanne M Richardson, MSc RAC ELS, Suzanne G Demko, Terrance L Thomas, Theresa Kirkham (NMI), Thomas J Arista, Torrance J Slayton, Tracy J Washington, Travis M Beard, Tricia S Martinez, Tuan A Nguyen, Vivian Garcia, William D Bassett, Jr, William H Shackelford, William V Millar, Xikui Chen (nmi), PhD, Young M Yoon, Youngjd, Zerita White, Zhong Li, PhD

Joel D Martinez's Documents

Publish Date Document Type Title
September, 2014 FDA 483 Stillmeadow Incorporated - Form 483, 2014-09-19
January, 2001 EIR Dr. H. Jakubek - EIR, 2001-02-20
March, 2001 EIR Walter Chase, MD/Clin Inv - EIR, 2001-03-02
January, 2006 FDA 483 IRB for the Baylor College of Medicine - Form 483, 2006-01-11
September, 2006 FDA 483 Response INCELL Corporation LLC - Form 483R, 2006-10-20
December, 2013 FDA 483 Worldwide Clinical Trials Early Phase Services, LLC - Form 483, 2013-12-20
October, 2000 EIR David R Talley, MD/Clin Inv - EIR, 2000-10-03
February, 2003 FDA 483 Response Victor Gonzalez, MD -Clinical Investigator - Form 483R, 2003-03-07
August, 2006 EIR Francis X Burch, M.D. - EIR, 2006-08-24
August, 2000 FDA 483 The University of Oklahoma - Form 483, 2000-08-04
June, 2001 EIR Paul Ratner, Dr/Clin Inv - EIR, 2001-06-07
February, 2003 FDA 483 Valley Retina Institute - Form 483, 2003-02-28
December, 2004 FDA 483 John R Graybill, Md - Form 483, 2004-12-20
March, 2013 EIR Burzynski Research Institute - EIR, 2013-03-15
February, 2003 EIR Victor Gonzalez, MD -Clinical Investigator - EIR, 2003-02-28
April, 2000 EIR KP Ganeshappa, MD - EIR, 2000-04-13
September, 2006 EIR INCELL Corporation LLC - EIR, 2006-09-19
January, 2001 FDA 483 Response Dr. M. Fouche - Form 483R, 2001-01-26
February, 2000 FDA 483 Response Michael Rud Lassen M.D. - Form 483R, 2000-05-04
January, 2001 FDA 483 Response sanofi chimie - Form 483R, 2001-01-31
March, 2013 FDA 483 Response Stanislaw R Burzynski, MD - Form 483R, 2013-04-08
February, 2011 FDA 483 Worldwide Clinical Trials Early Phase Services, LLC - Form 483, 2011-02-17
April, 2001 EIR Dr. Trevor Winter - EIR, 2001-04-27
October, 2018 EIR Worldwide Clinical Trials Early Phase Services, LLC - EIR, 2018-10-17
October, 2016 FDA 483 Israel Hartman, M.D. - Form 483, 2016-10-28
August, 2003 EIR Dr. Salman Al-Shukri - EIR, 2003-09-11
February, 2002 EIR BRI Institutional Review Board, Inc. - EIR, 2002-02-15
May, 2014 FDA 483 ICON Early Phase Services, LLC - Form 483, 2014-05-02
January, 2000 EIR Mark S Kipnes, Dr/Clinv - EIR, 2000-01-06
June, 2015 FDA 483 Biocon Biologics Limited - Form 483, 2015-06-16
September, 2001 EIR Matthew Medlock, MD - EIR, 2001-09-20
October, 2003 FDA 483 Sherwyn Schwartz MD - Form 483, 2003-10-22
November, 2004 FDA 483 MD Anderson Cancer Center - Form 483, 2004-11-02
June, 2016 FDA 483 Richard A. Pollak, DPM - Form 483, 2016-06-02
August, 2001 FDA 483 Stanislaw R Burzynski, MD - Form 483, 2001-08-10
April, 2002 EIR Richard M Evans, MD - EIR, 2002-04-01
June, 2014 FDA 483 Mario R. Juarez, M.D./ Panacea Clinical Research - Form 483, 2014-06-20
August, 2004 FDA 483 Prof. Dr. Valdir Tadini - Form 483, 2004-08-20
June, 2000 FDA 483 Worldwide Clinical Trials Early Phase Servcies/Bioanalytical Sciences, Inc. - Form 483, 2000-06-30
January, 2001 FDA 483 Response Dr. H. Jakubek - Form 483R, 2001-02-06
April, 2012 FDA 483 Celltex Therapeutics Corporation - Form 483, 2012-04-27
January, 2001 FDA 483 Polyclinique Sevigne - Form 483, 2001-01-26
February, 2002 FDA 483 BRI Institutional Review Board, Inc. - Form 483, 2002-02-15
September, 2006 EIR UTMB-Galveston - EIR, 2006-09-29
August, 2012 EIR Richard L. Wasserman, M.D. - EIR, 2012-08-17
August, 2004 EIR Dr. Valdir Tadini - EIR, 2004-09-20
October, 2003 FDA 483 Response Sherwyn L Schwartz, M.D. - Form 483R, 2003-10-22
October, 2003 EIR Sherwyn L Schwartz, M.D. - EIR, 2003-10-22
November, 2011 FDA 483 Norman Kalmin, M.D. - Form 483, 2011-11-09
October, 2000 EIR William C Campainge, DVM/Clinv - EIR, 2000-10-10
June, 2001 EIR Michael T. Jarratt, MD - EIR, 2001-06-21
May, 2001 FDA 483 Response Dr. Gordon Greenberg - Form 483R, 2001-05-16
November, 2004 EIR Massimo Cristofanilli, MD - EIR, 2004-11-03
October, 2015 FDA 483 Response Marc H. Weiner, M.D. - Form 483R, 2015-10-16
August, 2014 EIR Dr. Robert C. Read - EIR, 2014-08-22
October, 2000 FDA 483 Urology San Antonio - Form 483, 2000-10-03
November, 2004 EIR MD Anderson Cancer Center - EIR, 2004-11-02
August, 2014 FDA 483 Dr. Robert C. Read - Form 483, 2014-08-22
January, 2001 EIR Dr. M. Fouche - EIR, 2001-02-20
May, 2001 FDA 483 Mount Sinai Hospital - Form 483, 2001-05-10
January, 2000 FDA 483 Response Herve Sors M.D. - Form 483R, 2000-05-24
October, 2018 FDA 483 Worldwide Clinical Trials Early Phase Services, LLC - Form 483, 2018-10-17
March, 2015 FDA 483 S.R. Burzynski Manufacturing Facility - Form 483, 2015-03-19
May, 2014 EIR Emanuel Calenoff, M.D. - EIR, 2014-05-22
November, 2001 FDA 483 San Antonio Center for Clinical Research - Form 483, 2001-11-29
July, 2014 FDA 483 Response Alcon Research LLC - Form 483R, 2014-08-14
May, 2001 EIR Dr. Gordon Greenberg - EIR, 2001-06-01
February, 2000 EIR Michael Rud Lassen M.D. - EIR, 2000-03-07
July, 2014 EIR Alcon Research LLC - EIR, 2014-07-24
March, 2002 FDA 483 Response Worldwide Clinical Trials Early Phase Servcies/Bioanalytical Sciences, Inc. - Form 483R, 2002-03-27
December, 2002 FDA 483 International Association for Colon Hydrotherapy - Form 483, 2002-12-18
April, 2000 FDA 483 Digestive Diseases Center - Form 483, 2000-04-13
March, 2002 FDA 483 Worldwide Clinical Trials Early Phase Servcies/Bioanalytical Sciences, Inc. - Form 483, 2002-03-07
January, 2001 EIR sanofi chimie - EIR, 2001-02-20
March, 2013 FDA 483 Burzynski Research Institute - Form 483, 2013-03-15
June, 2002 EIR Patrick H Peters, Jr, MD - EIR, 2002-06-19
June, 2000 EIR Worldwide Clinical Trials Early Phase Servcies/Bioanalytical Sciences, Inc. - EIR, 2000-06-30
November, 2000 EIR Scirex Corp - EIR, 2000-11-22
March, 2013 EIR Stanislaw R Burzynski, MD - EIR, 2013-03-15
December, 2002 EIR International Association for Colon Hydrotherapy - EIR, 2002-12-18
January, 2002 EIR David W. Brown, MD - EIR, 2002-01-19
May, 2017 FDA 483 Michael G. Winnie, M.D./ 3rd Coast Research Associates - Form 483, 2017-05-10
April, 2002 EIR Francis X Burch, M.D. - EIR, 2002-04-18
August, 2004 EIR Dr. Carlos Isaia Filho - EIR, 2004-09-10
May, 2014 FDA 483 Emanuel Calenoff, M.D. - Form 483, 2014-05-22
March, 2013 FDA 483 Response Burzynski Research Institute - Form 483R, 2013-04-05
July, 2014 FDA 483 Alcon Research LLC - Form 483, 2014-07-24
March, 2011 EIR PETNET SOLUTIONS, INC. - EIR, 2011-03-11
September, 2006 FDA 483 INCELL Corporation LLC - Form 483, 2006-09-19
November, 2001 EIR Francis X Burch, M.D. - EIR, 2001-11-29
July, 2009 EIR Dowling ("Dow") B. Stough, IV, M.D. - EIR, 2009-07-24
June, 2012 FDA 483 Mark S. Kipnes. M.D. - Form 483, 2012-06-27
November, 2000 FDA 483 Response Scirex Corp - Form 483R, 2000-12-11
September, 2014 EIR Stillmeadow Incorporated - EIR, 2014-09-19
April, 2002 FDA 483 Medical Center Ophthalmology Associates - Form 483, 2002-04-01
March, 2013 FDA 483 Stanislaw R Burzynski, MD - Form 483, 2013-03-15
June, 2011 FDA 483 ICON Early Phase Services, LLC - Form 483, 2011-06-28
August, 2003 FDA 483 Dr. Salman Al-Shukri - Form 483, 2003-08-07
June, 2014 EIR Mario R. Juarez, M.D./ Panacea Clinical Research - EIR, 2014-06-20
October, 2015 FDA 483 Marc H. Weiner, M.D. - Form 483, 2015-10-06
March, 2000 EIR Paul Ratner, Dr/Clin Inv - EIR, 2000-03-02
May, 2002 EIR Prof. Jean-Louis Balmes (Paille) - EIR, 2002-06-11
August, 2014 FDA 483 Response Dr. Robert C. Read - Form 483R, 2014-09-04
January, 2000 EIR Herve Sors M.D. - EIR, 2000-01-28
March, 2002 EIR Worldwide Clinical Trials Early Phase Servcies/Bioanalytical Sciences, Inc. - EIR, 2002-03-07
September, 2005 EIR Mark S. Lee, M.D. - EIR, 2005-09-22
January, 2001 FDA 483 Krankenhaus der Barmherzigen - Form 483, 2001-01-19
November, 2000 FDA 483 Scirex Corp - Form 483, 2000-11-22
November, 2011 EIR Norman Kalmin, M.D. - EIR, 2011-11-09
October, 2001 EIR Thomas C Vaughn, MD - EIR, 2001-10-09
April, 2001 EIR Dr. Trevor Winter - EIR, 2001-04-26
November, 2004 FDA 483 Massimo Cristofanilli, MD - Form 483, 2004-11-03
December, 2000 EIR Central Texas Health Research - EIR, 2000-12-07
February, 2002 EIR David H Gordon, MD - EIR, 2002-02-28
June, 2001 FDA 483 Michael T. Jarratt, MD - Form 483, 2001-06-21

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more